These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 30872752)

  • 1. Six novel immunoglobulin genes as biomarkers for better prognosis in triple-negative breast cancer by gene co-expression network analysis.
    Hsu HM; Chu CM; Chang YJ; Yu JC; Chen CT; Jian CE; Lee CY; Chiang YT; Chang CW; Chang YT
    Sci Rep; 2019 Mar; 9(1):4484. PubMed ID: 30872752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of differentially expressed genes between triple and non-triple-negative breast cancer using bioinformatics analysis.
    Zhai Q; Li H; Sun L; Yuan Y; Wang X
    Breast Cancer; 2019 Nov; 26(6):784-791. PubMed ID: 31197620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integration of whole-genome sequencing and functional screening identifies a prognostic signature for lung metastasis in triple-negative breast cancer.
    Xie G; Yang H; Ma D; Sun Y; Chen H; Hu X; Jiang YZ; Shao ZM
    Int J Cancer; 2019 Nov; 145(10):2850-2860. PubMed ID: 30977117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of tRNA-derived small noncoding RNAs as potential biomarkers for prediction of recurrence in triple-negative breast cancer.
    Feng W; Li Y; Chu J; Li J; Zhang Y; Ding X; Fu Z; Li W; Huang X; Yin Y
    Cancer Med; 2018 Oct; 7(10):5130-5144. PubMed ID: 30239174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated network analysis and machine learning approach for the identification of key genes of triple-negative breast cancer.
    Naorem LD; Muthaiyan M; Venkatesan A
    J Cell Biochem; 2019 Apr; 120(4):6154-6167. PubMed ID: 30302816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk stratification of triple-negative breast cancer with core gene signatures associated with chemoresponse and prognosis.
    Kim EK; Park AK; Ko E; Park WY; Lee KM; Noh DY; Han W
    Breast Cancer Res Treat; 2019 Nov; 178(1):185-197. PubMed ID: 31342312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coexpression Network Analysis of Genes Related to the Characteristics of Tumor Stemness in Triple-Negative Breast Cancer.
    Suo HD; Tao Z; Zhang L; Jin ZN; Li XY; Ma W; Wang Z; Qiu Y; Jin F; Chen B; Cao Y
    Biomed Res Int; 2020; 2020():7575862. PubMed ID: 32766313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening and identification of potential biomarkers in triple-negative breast cancer by integrated analysis.
    Guo J; Gong G; Zhang B
    Oncol Rep; 2017 Oct; 38(4):2219-2228. PubMed ID: 28849078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of prognostic signatures in triple-negative breast cancer based on the differential expression analysis via NanoString nCounter immune panel.
    Lim GB; Kim YA; Seo JH; Lee HJ; Gong G; Park SH
    BMC Cancer; 2020 Nov; 20(1):1052. PubMed ID: 33138797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene expression in triple-negative breast cancer in relation to survival.
    Wang S; Beeghly-Fadiel A; Cai Q; Cai H; Guo X; Shi L; Wu J; Ye F; Qiu Q; Zheng Y; Zheng W; Bao PP; Shu XO
    Breast Cancer Res Treat; 2018 Aug; 171(1):199-207. PubMed ID: 29748761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel key genes in triple-negative breast cancer identified by weighted gene co-expression network analysis.
    Chen J; Qian X; He Y; Han X; Pan Y
    J Cell Biochem; 2019 Oct; 120(10):16900-16912. PubMed ID: 31081967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A seven-gene signature can predict distant recurrence in patients with triple-negative breast cancers who receive adjuvant chemotherapy following surgery.
    Park YH; Jung HH; Do IG; Cho EY; Sohn I; Jung SH; Kil WH; Kim SW; Lee JE; Nam SJ; Ahn JS; Im YH
    Int J Cancer; 2015 Apr; 136(8):1976-84. PubMed ID: 25537444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene regulatory pattern analysis reveals essential role of core transcriptional factors' activation in triple-negative breast cancer.
    Min L; Zhang C; Qu L; Huang J; Jiang L; Liu J; Pinello L; Yuan GC; Shou C
    Oncotarget; 2017 Mar; 8(13):21938-21953. PubMed ID: 28423538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-expression network analysis identified candidate biomarkers in association with progression and prognosis of breast cancer.
    Zhou Q; Ren J; Hou J; Wang G; Ju L; Xiao Y; Gong Y
    J Cancer Res Clin Oncol; 2019 Sep; 145(9):2383-2396. PubMed ID: 31280346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adipophilin expression is an independent marker for poor prognosis of patients with triple-negative breast cancer: An immunohistochemical study.
    Yoshikawa K; Ishida M; Yanai H; Tsuta K; Sekimoto M; Sugie T
    PLoS One; 2020; 15(11):e0242563. PubMed ID: 33201923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identified the novel resistant biomarkers for taxane-based therapy for triple-negative breast cancer.
    Chou CW; Huang YM; Chang YJ; Huang CY; Hung CS
    Int J Med Sci; 2021; 18(12):2521-2531. PubMed ID: 34104083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of triple-negative breast cancer radiosensitive gene signature and validation based on transcriptome analysis.
    Wushou A; Jiang YZ; Hou J; Liu YR; Guo XM; Shao ZM
    Breast Cancer Res Treat; 2015 Nov; 154(1):57-62. PubMed ID: 26476726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of the BAD pathway is a marker of triple-negative status and poor outcome.
    Boac BM; Abbasi F; Ismail-Khan R; Xiong Y; Siddique A; Park H; Han M; Saeed-Vafa D; Soliman H; Henry B; Pena MJ; McClung EC; Robertson SE; Todd SL; Lopez A; Sun W; Apuri S; Lancaster JM; Berglund AE; Magliocco AM; Marchion DC
    Sci Rep; 2019 Nov; 9(1):17496. PubMed ID: 31767884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Machine Learning Model to Predict the Triple Negative Breast Cancer Immune Subtype.
    Chen Z; Wang M; De Wilde RL; Feng R; Su M; Torres-de la Roche LA; Shi W
    Front Immunol; 2021; 12():749459. PubMed ID: 34603338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CYPOR is a novel and independent prognostic biomarker of recurrence-free survival in triple-negative breast cancer patients.
    Pedersen MH; Hood BL; Ehmsen S; Beck HC; Conrads TP; Bak M; Ditzel HJ; Leth-Larsen R
    Int J Cancer; 2019 Feb; 144(3):631-640. PubMed ID: 30110125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.